Clinical trials: Gastric (Stomach) Cancer
Locally Advanced Gastric Carcinoma
Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell
Background Local advanced gastric carcinoma (LAGC) is suggested to be potentially cured by R0 resection, and neoadjuvant chemotherapy can increase the R0 resection rate but not enough.
- Trial name
- NCT02048540
- Testing
- Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Chinese PLA General Hospital
Gastric Cancer
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or…
- Trial name
- NCT07025889
- Testing
- IBI343, Sintilimab, Oxaliplatin
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
The Patients With Gastric Cancer Who Are Scheduled to Receive Laparoscopy Assisted Gastrectomy
Comparison of Analgesic Efficacy and Occurrence of Emesis Among Different Background Infusion and Bolus Administration Regimens of Fentanyl Based Intravenous Patient-controlled Analgesia in Patients After Laparoscopic Assisted Gastrectomy - a Randomized Blind Study -
Fentanyl based intravenous patient controlled analgesia(PCA)is popular method for postoperative pain control, but information regarding optimal dose of fentanyl in IV PCA is currently lacking.
- Trial name
- NCT01863355
- Testing
- B0 group: bolus 0.6mcg/kg without background infusion, BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr, BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr
- Where
- South Korea
- Volunteers
- 225 people
- Sponsor
- Yonsei University
Gastrointestinal Cancer
The Status of Immune Checkpoints at Gastrointestinal Cancer
Colorectal cancers are the third most common cancer in the world. In advanced stages of colorectal cancers, peritoneal carcinomatosis and intraabdominal acid development occur.
- Trial name
- NCT04566848
- Testing
- Flow cytometric analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul Training and Research Hospital
Adenocarcinoma
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
This study is a multicenter non-interventional observational retrospective study with secondary data collection
- Trial name
- NCT05892926
- Where
- 31 sites in Russia
- Volunteers
- 204 people
- Sponsor
- AstraZeneca
Stomach Neoplasm
Gastric Cancer' Textbook Oncological Outcome and Tumor Board Performance
The goal of this observational, no-profit, spontaneous, retrospective, monocentric study is to compare surgical and oncologic outcomes in patients affected by gastric cancer before and after the institution of the Tumor Board, a…
- Trial name
- GaC-TOP (NCT06923449)
- Testing
- Multidisciplinary Tumor Board
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
Gastric Cancer Patients Undergoing Gastrectomy
Single-port Robotic Radical Gastrectomy for Gastric Cancer
This study is a single-center, phase 2a exploratory clinical study based on IDEAL framework. The intraoperative and postoperative complications were analyzed to evaluate the safety, feasibility and clinical efficacy of…
- Trial name
- NCT07237126
- Testing
- Single-port Robotic Radical Gastrectomy for Gastric Cancer
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Stomach Neoplasms
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent/metastatic gastric cancer,
- Trial name
- NCT07309185
- Testing
- Adebrelimab, Irinotecan, Malic acid Famitinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shandong Tumor Hospital
Helicobacter Pylori Infection, Dysbiosis
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
Helicobacter pylori (H. pylori) infection is the major cause of gastritis, peptic ulcer disease, and gastric cancer in adults. Bismuth-based quadruple therapy is recommended by a recent review to be the first-line treatment for…
- Conditions
- Helicobacter Pylori Infection, Dysbiosis, Probiotics
- Trial name
- Bsm10 (NCT04527055)
- Testing
- Bismuth Subcitrate 120 MG Oral Tablet, Lactobacillus acidophilus and Bifidobacterium lactis Bb12, Esomeprazole 40mg
- Where
- Taiwan
- Volunteers
- 312 people
- Sponsor
- National Cheng-Kung University Hospital
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
This phase II trial is studying erlotinib hydrochloride to see how well it works in treating patients with advanced esophageal cancer or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT00045526
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
ERAS for Gastric Cancer Patients After NACT
Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress…
- Trial name
- NCT06365814
- Testing
- enhanced recovery after surgery, conventional perioperative management
- Where
- China
- Volunteers
- 252 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Pancreatic Cancer, Gastric Cancer
COVID - 19 and Advanced Gastro-intestinal Cancer Treatment
A multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a…
- Conditions
- Pancreatic Cancer, Gastric Cancer, Esophagus Cancer, Colorectal Cancer
- Trial name
- COVID - AGICT (NCT04686747)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- S.M. Misericordia Hospital
Gastric Cancer, Surgery
The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer
The main purpose of this study is to evaluate the effect of extensive lymphadenectomy procedure in treatment of gastric cancer. This study is designed as a open-label, multi-centers, randomized controlled trial.
- Conditions
- Gastric Cancer, Surgery, Effects of Chemotherapy
- Trial name
- NCT02423278
- Testing
- Radical Gastrectomy Plus D2 Lymphadenectomy, Radical Gastrectomy Plus D4 Lymphadenectomy, S-1+Oxaliplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Gastric Cancer
Metronomic Capecitabine in Stage III Gastric Cancer
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
- Trial name
- NCT06313567
- Testing
- Metronomic capecitabine group, Observation
- Where
- China
- Volunteers
- 722 people
- Sponsor
- Fudan University
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Gastric Cancer, Oesophageal Carcinoma
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric…
- Trial name
- NCT07692204
- Testing
- SAR445877
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sanofi
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT05836584
- Testing
- Atezolizumab, Biospecimen Collection, Capecitabine
- Where
- 133 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Neoplasms
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer
Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1 and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks.
- Trial name
- TIROX2 (NCT00512681)
- Testing
- Irinotecan, Oxaliplatin, TS-1
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- National Cancer Center, Korea
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called GEJ cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GLOW (NCT03653507)
- Testing
- zolbetuximab, oxaliplatin, capecitabine
- Where
- 165 sites in United States, Argentina and 16 more
- Volunteers
- 507 people
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.